Antiproteinuric Agents and Fabry Disease

Completed

Conditions studied: Fabry Disease, Proteinuria

In brief

Fabry disease is a rare disorder that often has kidney involvement with increased urine protein excretion. Proteinuria is recognized as an important risk factor for progression of chronic kidney disease. Our hypothesis is that using drugs that reduce urine protein excretion (ACE inhibitors and ARBs) will have a beneficial effect on patients with Fabry disease who already are receiving enzyme replacement therapy. A longitudinal, observational study is being undertaken to determine the utility of these agents in Fabry disease, realizing that these agents are primarily indicated for reducing systemic blood pressure, and most patients with Fabry disease have relatively low blood pressures at baseline.

Key facts

Study ID

NCT00343577

Run by

University of Alabama at Birmingham

People needed

12

Starts

2001-01-01

Expected to finish

2006-12-01

Last updated by the study team

2013-11-19

Who can join

Age: 14 and older, up to 95. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• genetically confirmed Fabry disease
• institution of commercially available agalsidase-beta

You may not qualify if…

• s/p kidney transplant

Where it is running

• University of Alabama at Birmingham — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.